Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $22.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target cut by JMP Securities from $23.00 to $22.00 in a report published on Tuesday, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating for the company in a report on Thursday, February 8th. StockNews.com cut shares of Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, April 6th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $19.00.

Enanta Pharmaceuticals Stock Down 10.3 %

NASDAQ ENTA opened at $13.10 on Tuesday. Enanta Pharmaceuticals has a 52 week low of $8.08 and a 52 week high of $36.04. The stock has a market capitalization of $277.20 million, a PE ratio of -2.00 and a beta of 0.54. The firm has a 50 day moving average of $14.91 and a two-hundred day moving average of $12.08.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. On average, equities research analysts expect that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its position in Enanta Pharmaceuticals by 417.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,281 shares during the last quarter. Clearstead Advisors LLC purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $57,000. Quantbot Technologies LP raised its position in Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $113,000. Finally, Laurion Capital Management LP purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $126,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.